Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 55/100

ASX ANNOUNCEMENT 13 November 2025 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("the Company") advises that it has received

Key Takeaway: Alterity Therapeutics Limited has disclosed receipt of a notice from Regal Funds Management Asia Pte Limited regarding long equity derivative positions under the Australian Takeovers Panel Guidance Note 20. The notice pertains to two funds managed by Regal, namely the Amazon Market Neutral Fund and the Zambezi Absolute Return Fund. The disclosed positions include 50,000,000 ordinary shares as of November 10, 2025, equivalent to 0.46% of total shares, with no material changes to prior disclosures reported.

Market Sentiment Analysis

Full Press Release Details

Disclosure under Takeovers
Note 20: Equity Derivatives
Alterity Therapeutics Limited ACN 080
699 065 (ASX: ATH, NASDAQ: ATHE) ("the Company") advises that it has received the attached notice from Regal Funds Management
Asia Pte Limited which was provided to the Company pursuant to the Australian Takeovers Panel Guidance Note 20 - Equity Derivatives.
Authorised for release by:
Alterity Therapeutics
For further information please contact:
Investor Relations Advisory Solutions
Alterity Therapeutics Limited
Level 14, 350 Collins Street, Melbourne,
Victoria 3000 Australia
Dear Alterity Therapeutics ltd,
Disclosure of Long Equity Derivative Positions
We refer to Guidance Note 20: Equity Derivatives (GN20),
issued by the Australian Takeovers Panel. Terms not defined in this notice have the meanings given to them in GN20.
GN20 relevantly provides that the non-disclosure of
long positions, including long equity derivative positions, may give rise to unacceptable circumstances. Regal Funds Management Asia Pte
Limited, as investment manager of Amazon Market Neutral Fund and Zambezi Absolute Return Fund (the Funds), discloses the following
information on behalf of the Funds.
Identity of the taker: Amazon Market Neutral Fund Zambezi Absolute Return Fund
Relevant security: Ordinary shares in Alterity Therapeutics ltd
Price (including reference price, strike price, option price etc as appropriate): Not applicable
Entry date and number of securities to which the derivative relates: Total number of securities to which derivatives relate as at 10-Nov-2025: 50,000,000 (0.46%) Total number of securities to which derivatives relate as at 10-Nov-2025: 503,141,403 (4.63%)
Any material changes to information previously disclosed: No information previously disclosed Previous disclosure of below 5% on 31-Jul-2024
Relevant interests in securities: None
Long equity derivative positions and relevant interests held by the taker and its associates: The Funds have no other associates with a long equity derivative position or relevant interest in the company
Short equity derivative positions that offset physical positions: None
Short positions of more than 1% that have been acquired after a long position is disclosed, whether by notice or substantial holding notice: None
/s/ Greg Laughlin
Greg Laughlin
Chief Executive Officer
Regal Funds Management Asia Pte Limited

Frequently Asked Questions

What is the notice from Regal Funds Management about?

It discloses long equity derivative positions as per Guidance Note 20.

What companies are involved in the notice?

The notice involves Alterity Therapeutics Ltd and Regal Funds Management.

What does GN20 refer to?

GN20 refers to the Australian Takeovers Panel Guidance Note on equity derivatives.

How many securities are related to the derivatives?

A total of 50 million and 503 million securities are related to the derivatives.

Are there any material changes in previous disclosures?

No, there have been no material changes in previously disclosed information.

Last updated: Nov 13, 2025